Lilly 340B Data Mandate: Hospital Discount Fight
Decision brief
Answer first · skim in under a minute
Eli Lilly has issued a five-day ultimatum to over 1,000 hospitals, requiring them to submit claims data or risk losing access to 340B drug discounts. This move signals a significant escalation in the ongoing conflict between pharmaceutical manufacturers and healthcare providers over the controversial program.
Eli Lilly’s 340B data mandate is not a one-off media skirmish. The company’s SEC filings say claims-level data is ordinarily required for contract pharmacy sales under its limited distribution system, while Congress and courts keep rewriting the rules of engagement for hospitals and manufacturers.
Contents10 sections
Key Takeaways
- Lilly’s 2025 Form 10-K describes a Contract Pharmacy Limited Distribution System that ordinarily requires claims-level data for contract pharmacy channels.
- CRS cites more than $66 billion in 340B purchases in 2023, with DSH hospitals about 78% of volume—so manufacturer data rules hit hospital economics hard.
- Lilly sued HRSA on November 14, 2024 over rejection of a cash replenishment model; older contract pharmacy litigation remains on appeal.
- Hospital teams should treat unverified “ultimatum” tallies as secondary until confirmed in primary filings or agency letters.
What is Lilly’s disclosed 340B data mandate?
Lilly’s Form 10-K for the year ended December 31, 2025 says the company uses a Contract Pharmacy Limited Distribution System for 340B sales. Distribution of 340B-priced product is generally limited to covered entities and child sites, or—if there is no in-house outpatient pharmacy—to a single designated contract pharmacy.
The same filing states that claims-level data is ordinarily required for any contract pharmacy, with narrow exceptions such as certain “penny priced” insulin products when discounts pass through at the point of sale. Read the primary text in Lilly’s 2025 Form 10-K on SEC EDGAR.
Why are hospitals fighting manufacturer data demands?
340B was built to stretch scarce resources for safety-net providers. When manufacturers condition discount access on granular claims feeds, hospitals argue the burden and privacy risk chill legitimate contract pharmacy networks that serve uninsured and underinsured patients.
Manufacturers counter that claims data is needed to stop diversion and unlawful duplicate discounts with Medicaid. That tension is now the core of multi-year litigation summarized by the Congressional Research Service 340B litigation report.
How big is the economic stake?
CRS, citing HRSA figures, reports covered entities purchased more than $66 billion in 340B drugs in calendar year 2023. DSH hospitals alone accounted for about $51.9 billion, or roughly 78% of purchases.
- $66 billion+ 340B purchases in 2023 (CRS/HRSA)
- ~$51.9 billion from DSH hospitals (about 78%)
- November 14, 2024: Lilly sues HRSA over cash replenishment rejection
- January 2021: Lilly files Indiana suit over contract pharmacy advisory opinion
- January 2026: HHS selects Trulicity and Verzenio for IRA price negotiation effective 2028 (separate pricing pressure on the same franchise set)
Those dollars explain why a claims-data rule is a commercial lever, not a paperwork footnote.
What litigation still hangs over Lilly’s 340B model?
Lilly’s contingency notes describe a January 2021 Indiana lawsuit against HHS/HRSA over contract pharmacy requirements and ADR rules, with a Seventh Circuit appeal still pending in later disclosures. On November 14, 2024, Lilly sued HRSA again after the agency rejected a proposed cash replenishment model meant to replace opaque product replenishment.
Hospital counsel should map any new data request against those open cases and against HRSA’s stated program-integrity posture, while tracking federal pricing programs through CMS and HHS channels.
How should hospital and manufacturer teams respond?
Hospitals should inventory which Lilly NDCs move through contract pharmacies, confirm whether in-house outpatient pharmacies exist, and document what claims fields they already submit to payers. That inventory is the difference between a negotiated data feed and a sudden loss of ceiling-price inventory.
Manufacturer market access teams should assume peer companies will copy successful data templates. Align legal, 340B operations, and IR messaging so public claims match the 10-K description of the limited distribution system.
What remains unproven?
Secondary reports have described short hospital response windows and large hospital counts. Those operational details are not stated in the SEC excerpts above and should not be treated as settled fact without a primary letter, filing, or allowlisted wire. Focus analysis on disclosed distribution rules, purchase volume, and docketed litigation.
Related NovaPharma coverage
- Eli Lilly raises 2026 revenue guidance on Mounjaro demand
- Eli Lilly pipeline and deals: 2026 outlook
- Eli Lilly retatrutide Phase 3 competitive implications
Frequently Asked Questions
What does Eli Lilly disclose about 340B claims data?
In its 2025 Form 10-K, Lilly states that its Contract Pharmacy Limited Distribution System ordinarily requires claims-level data for any contract pharmacy and generally limits 340B-priced distribution to covered entities, child sites, or a single designated contract pharmacy when there is no in-house outpatient pharmacy.
How large is the 340B market Lilly is pushing against?
A Congressional Research Service report cites HRSA data that covered entities purchased more than $66 billion in 340B drugs in calendar year 2023, with DSH hospitals accounting for about 78% ($51.9 billion) of that total.
Is Lilly’s 340B litigation still active?
Yes. Lilly’s 10-K and later contingency disclosures describe ongoing litigation with HHS/HRSA over contract pharmacy policy, plus a November 14, 2024 suit over HRSA’s rejection of Lilly’s cash replenishment model. Outcomes remain pending.
Primary Sources
Eli Lilly pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
